Shanghai Nianxing Industrial Co., Ltd
China
Product Name: DMAPT
Price: Check
Purity: 98.0%
Stocking Period: 10 Day
Contact: Yang
Email: sales@echemcloud.com

870677-05-7

870677-05-7 structure

870677-05-7 structure

Name: DMAPT
Chemical Name: DMAPT
CAS Number: 870677-05-7
Molecular Formula: C₁₇H₂₇NO₃
Molecular Weight: 293.40
Catalog: Research Areas Cancer
Create Date: 2019-08-07 17:46:06
Modify Date: 2025-08-25 18:04:03
DMAPT (Dimethylamino Parthenolide), a water soluble analogue of Parthenolide (PTL), is an oral active NF-κB inhibitor, with a LD50 of 1.7 μM for cell population in AML cells. Has potential anti-cancer and anti-metastatic effect[1].

Name	DMAPT

Description	DMAPT (Dimethylamino Parthenolide), a water soluble analogue of Parthenolide (PTL), is an oral active NF-κB inhibitor, with a LD50 of 1.7 μM for cell population in AML cells. Has potential anti-cancer and anti-metastatic effect[1].
Related Catalog	Research Areas >> Cancer
Target	NF-κB[1].
In Vitro	DMAPT treatment decreased constitutive NF-κB binding activity, inhibits cell proliferation and viability of PC-3 and DU145 cells[2]. Treatment of PC-3 and DU145 cells with 5 and 4 μM DMAPT, respectively, increases the population doubling times of PC-3 prostate cancer cells from 23.0 ± 5.0 h to 42.0 ± 3.0 h and of the DU145 cells from 20.4 ± 2.2 h to 72.5 ± 24.8 h[2]. Cell Proliferation Assay[2] Cell Line: PC-3 and DU145 cells. Concentration: PC-3 cells (0, 2.5, 5 μM), DU145 cells (0 and 4 μM). Incubation Time: 24 and 48 hours. Result: Decreased constitutive NF-κB binding activity, inhibits cell proliferation and viability of PC-3 and DU145 cells.
In Vivo	Treatment with DMAPT (100 mg/kg, Oral gavage daily for 7 days) increases sensitivity of PC-3 tumor xenografts to X-rays[2]. DMAPT (100 mg/kg, Oral gavage thrice weekly from 42 to 300 days since birth) treatment slows normal tumor development in TRAMP mice, extending the time-to-palpable prostate tumor by 20%[3]. DMAPT further reduces the metastatic area below that of the water vehicle treatment group in lung tissues (0.10% ± 0.15 SD, 92% reduction, p = 0.0028) in TRAMP mice[3]. Animal Model: PC-3 tumor xenograft in athymic nude mice[2]. Dosage: 100 mg/kg. Administration: Oral gavage daily for 7 days. Result: Increased sensitivity of PC-3 tumor xenografts to X-rays. Animal Model: Six-week-old male TRAMP mice[3]. Dosage: 100 mg/kg. Administration: Oral gavage thrice weekly from 42 to 300 days since birth. Result: Slowed normal tumor development in TRAMP mice, extending the time-to-palpable prostate tumor by 20%.
References	[1]. Neelakantan S, et al. Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-kappaB inhibitor, DMAPT (LC-1). Bioorg Med Chem Lett. 2009 Aug 1;19(15):4346-9. [2]. Mendonca MS, et al. DMAPT inhibits NF-κB activity and increases sensitivity of prostate cancer cells to X-rays in vitro and in tumor xenografts in vivo. Free Radic Biol Med. 2017 Nov;112:318-326. [3]. Morel KL, et al. Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide. Clin Exp Metastasis. 2018 Oct;35(7):649-661.

Molecular Formula	C₁₇H₂₇NO₃
Molecular Weight	293.40

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.